Short answer
Parabilis Medicines Inc (PBLS) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $2M with net income of −$44M.
Q3 2026 key financials · XBRL
- Revenue
- $2M
- +1328.4% QoQ
- Net income
- −$44M
- +54.5% QoQ
- Operating margin
- -2589.2%
- EPS (diluted)
- $5.35
- +160.4% QoQ
Source: XBRL data from the Parabilis Medicines Inc (PBLS) Q3 2026 10-Q on SEC EDGAR. USD.
Parabilis Medicines Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $2.1M vs $0, including $0.7M Regeneron and $1.4M Altos collaboration revenue
- Net loss $44.5M vs $33.5M, operating expenses $56.9M vs $34.8M
- R&D highest spender: zolucatetide $17.8M, up 118.9% YoY; ERG degrader $1.2M, down 16.1%
- Cash, equivalents and marketable securities $1,072.9M, funding operations into 2030
- IPO and private placement generated $787.9M net; Regeneron upfront payment $50.0M
- Near-term outlook: Phase 3 zolucatetide trial planned for first half 2027; substantial additional funding required
Risk Factors
- Newly added regulatory risk: June 2026 FDA draft guidance may require additional evidence despite single-trial pathway
- Most material clinical update: March 2026 injectable formulation paused after Grade 1 and Grade 2 injection-site reactions
- AI compliance risk: EU Artificial Intelligence Act obligations became effective August 2, 2026
- Operational risk: Alcami remains the sole drug-product supplier
- Financial risk: $1,072.9 million cash, cash equivalents and marketable securities funding operations into 2030
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.